2019
DOI: 10.1787/7ca86a34-en
|View full text |Cite
|
Sign up to set email alerts
|

Adverse Outcome Pathway on inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment

Abstract: This Adverse Outcome Pathway (AOP) on Inhibition of Na+/I-symporter (NIS) leads to learning and memory impairment, has been developed under the auspices of the OECD AOP Development Programme, overseen by the Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST), which is an advisory group under the Working Group of the National Coordinators for the Test Guidelines Programme (WNT). The AOP has been reviewed internally by the EAGMST, externally by experts nominated by the WNT, and has been e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 325 publications
(412 reference statements)
0
3
0
Order By: Relevance
“…However, to date, only AOPs 42 and 54 (presenting direct MoAs) have been endorsed by the OECD (Crofton et al 2019;Rolaki et al 2019), whereas AOP 8, 134, and 152 (with the latter two presenting indirect MoAs) are denoted as "under development" (Table 1). Therefore, the sequence of events described in these AOPs, up to their adverse outcomes, should not be considered conclusive yet.…”
Section: Thyroid-related Aops Including Adverse Neurodevelopmental Outcomesmentioning
confidence: 99%
See 1 more Smart Citation
“…However, to date, only AOPs 42 and 54 (presenting direct MoAs) have been endorsed by the OECD (Crofton et al 2019;Rolaki et al 2019), whereas AOP 8, 134, and 152 (with the latter two presenting indirect MoAs) are denoted as "under development" (Table 1). Therefore, the sequence of events described in these AOPs, up to their adverse outcomes, should not be considered conclusive yet.…”
Section: Thyroid-related Aops Including Adverse Neurodevelopmental Outcomesmentioning
confidence: 99%
“…AOP 42: Inhibition of thyroid peroxidase (TPO) and subsequent adverse neurodevelopmental outcomes in mammals Supporting evidence is mostly derived from in vitro studies and rodent studies, while indicating that "it is well accepted" that specific key events also occur in humans; the main body of experimental evidence stems from studies with the very potent pharmaceutical TPO inhibitors propylthiouracil and methimazole. Crofton et al (2019) and Rolaki et al (2019). By comparison, AOP 8, AOP 134, and AOP 152 are research drafts, and AOP 8 has the author status "not under active development" indicating that it has been dormant since an early draft stage.…”
Section: Introduction To the Moa And Aop Conceptsmentioning
confidence: 99%
“…A limited number of AOPs have been developed to the level where they have been endorsed by the OECD Working Party on Hazard Assessment and the Working Group of National Coordinators of the Test Guidelines Programme (WPHA/WNT). This includes the AOP initiated by inhibition of thyroperoxidase (TPO) and leading to adverse neurodevelopmental outcomes in mammals ( Crofton et al, 2019 ) and the AOP leading from inhibition of the Na+/I- symporter (NIS) to learning and memory impairment in mammals ( Rolaki et al, 2019 ). Five AOPs linking TPO and deiodinase inhibition to impaired swim bladder inflation in fish have recently been endorsed ( Vergauwen et al, 2022a ; Vergauwen et al, 2022b ; Vergauwen et al, 2022c ; Vergauwen et al, 2022d ; Vergauwen et al, 2022e ).…”
Section: Introductionmentioning
confidence: 99%